{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:36Z","timestamp":1781636256460,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Halle (Saale)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer is the most frequent source of brain metastases (BMs), with 20-40% of patients with non-small cell lung cancer (NSCLC) developing BMs during the course of disease. The NSCLC-GPA (Graded Prognostic Assessment), developed by Sperduto et al., aims to estimate overall survival (OS) in lung cancer patients with BMs based on multiple prognostic factors. This study aimed to validate the applicability and prognostic relevance of the updated 2022 NSCLC-GPA in a German clinical cohort, with particular attention to programmed death-ligand 1 (PD-L1) expression and treatment-related outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with NSCLC and BMs treated between 2020 and 2022 at a German university hospital. GPA scores were calculated using established parameters: age, Karnofsky Performance Status (KPS), number of BMs, presence of extracranial metastases (ECM), EGFR and ALK mutation status, and PD-L1 expression. Due to the low number of non-adenocarcinoma (NAC) cases in our cohort, only patients with adenocarcinoma (AC) were included. Univariate and multivariate Cox regression models, log-rank tests, and Kaplan\u2013Meier curves for illustrative purposes were used to evaluate associations between prognostic factors and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 110 AC patients met the inclusion criteria. Median OS was 10 months (range: 6-11). Patients with GPA scores of 0-1 and 1.5-2 had significantly worse outcomes compared with the reference group (GPA 3.5-4; median OS: 36 months), with median OS times of 3 and 8 months, respectively (HR: 8.34, 95% CI: 2.53-27.5,\n                      <jats:italic>p<\/jats:italic>\n                      =\u20090.0005 and HR: 5.24, 95% CI: 1.584-17.33,\n                      <jats:italic>p<\/jats:italic>\n                      =\u20090.0067). Patients with a GPA of 2.5-3 had a median OS of 22.5 months (HR: 1.6, 95% CI: 0.469-5.45,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.453), which was not statistically significant. Older age (\u2265\u200970 years; HR: 1.95, 95% CI: 1.23-3.11,\n                      <jats:italic>p<\/jats:italic>\n                      =\u20090.0047), low KPS (KPS\u2009\u2264\u200970; HR: 3.88, 95% CI: 2.33-6.46,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), a higher number of BMs (HR: 1.58, 95% CI: 1.03-2.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035), and the presence of ECM (HR: 2.62, 95% CI: 1.66-4.13,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) were all significantly associated with decreased OS. In the multivariate analysis, low KPS and ECM remained independently significant prognostic factors. PD-L1 expression showed no significant association with OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite shorter OS outcomes in our cohort, the 2022 NSCLC-GPA proved to be a valuable prognostic tool, with lower scores consistently associated with poorer outcomes. In addition, older age, low KPS, ECM, and a higher number of BMs were identified as prognostic factors, with low KPS and ECM remaining independent prognostic factors in the multivariate analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02805-0","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:48:42Z","timestamp":1771922922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the updated 2022 lung-GPA in NSCLC adenocarcinoma patients with brain metastases: analysis of prognostic factors in a German clinical cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Niklas","family":"Mittenbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Christian","family":"Philippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Medenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg Andreas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2805_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2805_CR2","unstructured":"Statistisches Bundesamt. Die 10 h\u00e4ufigsten Todesf\u00e4lle durch Krebs. 2023. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Todesursachen\/Tabellen\/sterbefaelle-krebs-insgesamt.html. Accessed 16 Oct 2024."},{"key":"2805_CR3","unstructured":"2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.who.int\/today, accessed [23.10.2024]. (Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F). https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf."},{"key":"2805_CR4","doi-asserted-by":"publisher","unstructured":"Alexander M, Kim SY, Cheng H, Update. 2020: Management of non-small cell lung cancer. Lung. 2020;198:897\u2013907. https:\/\/doi.org\/10.1007\/s00408-020-00407-5.","DOI":"10.1007\/s00408-020-00407-5"},{"key":"2805_CR5","unstructured":"Langer T. S3-Leitlinie Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms: Version 3.0 - M\u00e4rz 2024 AWMF-Registernummer: 020-007OL, pp. 35\u201341."},{"key":"2805_CR6","unstructured":"RKI. RKI \u2013 Krebs in Deutschland \u2013 2019\/2020: p. 16."},{"issue":"1","key":"2805_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25(1):45\u201352. https:\/\/doi.org\/10.5114\/wo.2021.103829. Epub 2021 Feb 23. PMID: 33911981; PMCID: PMC8063897.","journal-title":"Contemp Oncol (Pozn)"},{"key":"2805_CR8","unstructured":"2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.who.int\/today, accessed [DD Month YYYY]. (Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F). https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf. Accessed 24 Oct 2024."},{"key":"2805_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/nou099","volume":"17","author":"JL Villano","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2015;17:122\u20138. https:\/\/doi.org\/10.1093\/neuonc\/nou099.","journal-title":"Neuro Oncol"},{"key":"2805_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01436-2","author":"S-YM Liu","year":"2023","unstructured":"Liu S-YM, Zheng M-M, Pan Y, Liu S-Y, Li Y, Wu Y-L. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s13045-023-01436-2.","journal-title":"J Hematol Oncol"},{"key":"2805_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s41016-018-0149-0","author":"Q Liu","year":"2019","unstructured":"Liu Q, Tong X, Wang J. Management of brain metastases: history and the present. Chin Neurosurg Jl. 2019. https:\/\/doi.org\/10.1186\/s41016-018-0149-0.","journal-title":"Chin Neurosurg Jl"},{"key":"2805_CR12","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.jtocrr.2024.100655","volume":"5","author":"T Tozuka","year":"2024","unstructured":"Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R, et al. Immunotherapy with radiotherapy for brain metastases in patients with NSCLC: NEJ060. JTO Clin Res Rep. 2024;5:100655. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100655.","journal-title":"JTO Clin Res Rep"},{"key":"2805_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.wneu.2016.09.054","volume":"97","author":"G D\u2019Andrea","year":"2017","unstructured":"D\u2019Andrea G, Palombi L, Minniti G, Pesce A, Marchetti P. Brain metastases: surgical treatment and overall survival. World Neurosurg. 2017;97:169\u201377. https:\/\/doi.org\/10.1016\/j.wneu.2016.09.054.","journal-title":"World Neurosurg"},{"key":"2805_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3:827\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3834.","journal-title":"JAMA Oncol"},{"key":"2805_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"PW Sperduto","year":"2022","unstructured":"Sperduto PW, De B, Li J, Carpenter D, Kirkpatrick J, Milligan M, et al. Graded prognostic assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the Non-Small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors. Int J Radiat Oncol Biol Phys. 2022;114:60\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.03.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2805_CR16","unstructured":"2021. Blemings dplyr, A., Allen C.). https:\/\/dplyr.tidyverse.org. Accessed 23 Oct 2024."},{"key":"2805_CR17","unstructured":"2021. gtsummary: Presentation of summary statistics and results from statistical models (2.0.0). R Foundation for Statistical Computing. (DuGoff, E., Schuler, M., & D\u2019Agostino, M.). https:\/\/gtsummary.rstudio.com. Accessed 24 Oct 2024."},{"key":"2805_CR18","unstructured":"2021. Grolemund lubridate, G., Wickham H.). https:\/\/lubridate.tidyverse.org. Accessed 24 Oct 2024."},{"key":"2805_CR19","unstructured":"2021. survival: Survival analysis (3.7-0). R Foundation for Statistical Computing. (Therneau TM.). https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR20","unstructured":"2021. survminer: Drawing survival curves using ggplot2 (0.4.9). R Foundation for Statistical Computing. (Kassambara, A., & Kosinski, M.). https:\/\/cran.r-project.org\/web\/packages\/survminer\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR21","unstructured":"2021. tidyverse: Easily install and load the \u2018tidyverse\u2019 (2.0.0). R Foundation for Statistical Computing. (Wickham H.). https:\/\/tidyverse.tidyverse.org. Accessed 24 Oct 2024."},{"key":"2805_CR22","unstructured":"2021. Gohel readxl. V.). https:\/\/cran.r-project.org\/web\/packages\/readxl\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR23","unstructured":"2021. labelled: Label data frames and vectors (2.13.0). R Foundation for Statistical Computing. (Lepage J.). https:\/\/cran.r-project.org\/web\/packages\/labelled\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR24","unstructured":"2021. openxlsx: Read, write and edit Excel files (4.2.6.1). R Foundation for Statistical Computing. (Yoon J, Kim S.). https:\/\/cran.r-project.org\/web\/packages\/openxlsx\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR25","unstructured":"2021. Table 1: Create Table 1 for clinical papers (1.4.3). R Foundation for Statistical Computing. (Hoffman M, Hwang J.). https:\/\/cran.r-project.org\/web\/packages\/table1\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR26","unstructured":"2021. boot: Bootstrap R (1.3\u201330). R Foundation for Statistical Computing. (Efron B, Tibshirani RJ.). https:\/\/cran.r-project.org\/web\/packages\/boot\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR27","unstructured":"2021. flextable: Create and format tables in Word and PowerPoint documents (0.9.6). R Foundation for Statistical Computing. (Graham, N.). https:\/\/cran.r-project.org\/web\/packages\/flextable\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR28","unstructured":"2021. officer: Interact with Microsoft Word and PowerPoint documents (0.6.7). R Foundation for Statistical Computing. (Xie Y.). https:\/\/cran.r-project.org\/web\/packages\/officer\/index.html. Accessed 24 Oct 2024."},{"key":"2805_CR29","unstructured":"2021. broom: Convert statistical analysis objects into tidy tibbles (1.0.7). R Foundation for Statistical Computing. (Robinson D, Hayes A.). Accessed 24 Oct 2024."},{"key":"2805_CR30","unstructured":"2021. MatchIt. Nonparametric Preprocessing for Parametric Causal Inference (4.5.5). R Foundation for Statistical Computing. (Ho, D. E., Imai, K., King, G., & Stuart, E. A.). https:\/\/cran.r-project.org\/web\/packages\/MatchIt\/index.html."},{"key":"2805_CR31","unstructured":"Schr\u00f6der C, Windisch P, L\u00fctscher J, Zwahlen DR, F\u00f6rster R. Validation and discussion of clinical practicability of the 2022 graded prognostic assessment for NSCLC adenocarcinoma patients with brain metastases in a routine clinical cohort."},{"key":"2805_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.lungcan.2009.01.020","volume":"66","author":"L-H Hsu","year":"2009","unstructured":"Hsu L-H, Chu N-M, Liu C-C, Tsai SYC, You D-L, Ko J-S, et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer. 2009;66:262\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2009.01.020.","journal-title":"Lung Cancer"},{"key":"2805_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1556-0864(15)31609-9","volume":"1","author":"HA Wakelee","year":"2006","unstructured":"Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH. Survival differences by sex for patients with advanced Non-small cell lung cancer on Eastern cooperative oncology group trial 1594. J Thorac Oncol. 2006;1:441\u20136. https:\/\/doi.org\/10.1016\/S1556-0864(15)31609-9.","journal-title":"J Thorac Oncol"},{"key":"2805_CR34","doi-asserted-by":"publisher","first-page":"110405","DOI":"10.1016\/j.radonc.2024.110405","volume":"198","author":"JA Crouzen","year":"2024","unstructured":"Crouzen JA, Mast ME, Hakstege M, Broekman MLD, Baladi C, Mertens BJA, et al. External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer. Radiother Oncol. 2024;198:110405. https:\/\/doi.org\/10.1016\/j.radonc.2024.110405.","journal-title":"Radiother Oncol"},{"issue":"3","key":"2805_CR35","first-page":"727","volume":"10","author":"PD-1\/PD-L1 pathway","year":"2020","unstructured":"PD-1\/PD-L1 pathway. Current researches in cancer, Yanyan Han1, Dandan Liu2, Lianhong Li1. Am J Cancer Res. 2020;10(3):727\u201342. ISSN:2156\u20136976\/ajcr0108072.","journal-title":"Am J Cancer Res"},{"key":"2805_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2.","journal-title":"Mol Cancer"},{"key":"2805_CR37","doi-asserted-by":"publisher","unstructured":"Ngeow J, Leong SS, Gao F, Toh CK, Lim WT, Tan EH, Poon D. Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and\/or have poor performance status. Crit Rev Oncol Hematol 2010 Oct, 1:53\u201360. https:\/\/doi.org\/10.1016\/j.critrevonc.2009.10.005. Epub 2009 Nov 24. PMID: 19939700. (76).","DOI":"10.1016\/j.critrevonc.2009.10.005"},{"key":"2805_CR38","doi-asserted-by":"crossref","unstructured":"P\u00e9us D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inf Decis Mak. 13, 72. 1472-6947-13\u201372.","DOI":"10.1186\/1472-6947-13-72"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02805-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02805-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02805-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:46:22Z","timestamp":1781635582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02805-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2805"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02805-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6985982\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of the Medical Faculty of the Martin Luther University Halle-Wittenberg (reference number 2024-009). The committee raised no ethical or professional objections to the study. According to \u00a7\u00a017 KHG LSA, informed consent was waived due to the retrospective nature of the study, the use of pseudonymized data, and the disproportionate burden of obtaining individual consent. The committee emphasized the importance of data minimization and recommended anonymization of the data whenever possible. All procedures were conducted in accordance with the Declaration of Helsinki (2013 revision).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}